Showing results (31-40 of 52) with videos related to

Sort By:
Pageof 6
Pharmacological Research Communications|May 1, 1988
Constrictory activity of three new arginine-vasopressin (AVP) analogues (Ala-AVP, Ser-Ala-AVP, Thr-Ser-Ala-AVP) towards isolated rat tail artery as related to AVP aloneR Kalïszan, J Petrusewicz, W Juzwa, et al.
Pharmacological Research|February 1, 1992
New antagonists of the vasopressin receptor mediated contraction in rat tail arteryJ Petrusewicz, B Damasiewicz, R Kaliszan, et al.
Experientia|January 15, 1991
Cyclic and linear vasopressin V1 and V1/V2 antagonists containing arginine in the 4-positionW H Sawyer, B Lammek, A Misicka, et al.
The Journal of Peptide Research : Official Journal of the American Peptide Society|February 13, 2001
Analogs of oxytocin conformationally restricted in the N-terminal part of the moleculeE Lempicka, I Derdowska, B Jastrz bska, et al.
Journal of Medicinal Chemistry|January 1, 1989
2-O-alkyltyrosine derivatives of 1-deamino-arginine-vasopressin: highly specific and potent antidiuretic agonistsB Lammek, K Bankowski, A Misicka, et al.
The Journal of Peptide Research : Official Journal of the American Peptide Society|April 9, 2005
Analogues of arginine vasopressin and its agonist and antagonist modified in the N-terminal part of the molecule with l-beta-homophenylalanineD Sobolewski, W Kowalczyk, A Prahl, et al.
General Physiology and Biophysics|August 1, 1990
Stimulation of the sodium transport across the frog skin by three N-terminally extended arginine-vasopressinsJ Ponec, P Bakos, B Lichardus, et al.
General Physiology and Biophysics|December 1, 1990
Suppression of natriferic activity of the vasopressin molecule by modifications in positions 1, 2 and 4P Bakos, J Ponec, M Alexandrová, et al.
Science (New York, N.Y.)|April 3, 1981
Vasopressin analogs that antagonize antidiuretic responses by rats to the antidiuretic hormoneW H Sawyer, P K Pang, J Seto, et al.
The Journal of Pharmacy and Pharmacology|March 1, 1996
Surprising pharmacological activity of analogues designed by substitution of position 3 in arginine vasopressin (AVP) and 8-D-arginine vasopressin with L-2-napthylalanineB Lammek, E Konieczna, H I Trzeciak, et al.
Pageof 6